CCL5

CCL5

CCL5 Overview

Molecule Name
C-C motif chemokine 5
Synonyms
EoCP,Eosinophil chemotactic cytokine,SIS-delta,Small-inducible cytokine A5,T cell-specific protein P228,TCP228,D17S136E, SCYA5,CCL5,C-C motif chemokine 5 T-cell-specific protein RANTES
Drug Development Progress
Drugs in Clinical Trials2
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Beta-Chemokine RANTES,Regulated Upon Activation, Normally T-Expressed, And Presumably Secreted,RANTES,TCP228,SIS-Delta,SISd,Small-Inducible Cytokine A5,D17S136E,T Cell-Specific Protein P228,EoCP,C-C Motif Chemokine 5,C-C Motif Chemokine Ligand 5,CCL5,Small Inducible Cytokine A5 (RANTES),Chemokine (C-C Motif) Ligand 5,T-Cell Specific RANTES Protein,T-Cell Specific Protein P288,Small Inducible Cytokine Subfamily A (Cys-Cys), Member 5,Eosinophil Chemotactic Cytokine,T-Cell-Specific Protein RANTES,SCYA5,Chemokine CXCL5,MGC17164
Background
C-C chemokine ligand 5 (CCL5), also known as RANTES, is a target gene of NF-kappaB, and is expressed by T lymphocytes, macrophages, platelets, synovial fibroblasts, tubular epithelium, and certain types of tumour cells. CCL5 plays a role in recruiting a variety of leukocytes into inflammatory sites including T cells, macrophages, eosinophils, and basophils. CCL5 activity is mediated through its binding to CCR1, CCR3, and mainly CCR5.

CCL5 Product List

Species
  • Human(2)
Tag
  • Fc Tag(1)
  • Tag Free(1)
Host
  • E. coli(1)
  • HEK293(1)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • No(2)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&PriceAdd to Cart
CCL5
Human CCL5/RANTES Protein, Tag Free
Human
E. coli
SDS-PAGE
ELISA

$185.00

20ug
CCL5
Human CCL5/RANTES Protein, Fc Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$185.00

20ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AFX-5931AFX-5931Phase 2 ClinicalAfecta Pharmaceuticals Inc
Eczema
Details
MW-151MW01-9-034WH; MW-151; MW01-2-151SRMPhase 1 ClinicalUniversity Of Kentucky
Drug-Related Side Effects and Adverse Reactions; Poisoning
Details
Customer Reviews